secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001558370-24-015708
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hookipa Q3 net loss narrows to $13.8M; cash $60M; Phase 2 eseba-vec enrollment complete (68 pts)
--------------------------------------------------------------------------------

- Net loss $13.8M vs $19.1M YoY; revenue $4.7M (down from $6.9M) on Roche collaboration termination.
- Cash $60.0M at Sep 30, 2024 (from $117.5M Dec 2023); received $5M milestone from Gilead for HB-500 dosing.
- Phase 2 eseba-vec + pembrolizumab in HPV+ HNSCC enrolled 68 patients ahead of schedule; updated data at SITC 2024.
- First patients dosed in MSKCC Investigator Initiated Trial of eseba-vec as adjuvant therapy for HNSCC.
- Leadership: Malte Peters appointed CEO, Terry Coelho CFO in July; reverse stock split effected 1:10.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000155837024015708/0001558370-24-015708-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000155837024015708/hook-20241114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-015708

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer